On the stock market since 2011, it operates in the world of health and science. It has 23,833 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 10% a year over the last 4 years. Every year shown ended in profit.
The gap is $7.9B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
It pays out $0.28 per share each year — regular cash for whoever holds the stock.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, GRFS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GRFS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.